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The  long  awaited  all-oral  therapy  for hepatitis  C virus  infection  has  ofﬁcially  been  inaugurated  by  the
registration  of  the  hepatitis  C nucleotide  inhibitor  sofosbuvir  in  a combination  regimen  with  ribavirin.
More  recently,  the oral  array  to  treat  hepatitis  C has  been  enriched  by  the  arrival  of  the NS5A  inhibitors
ledipasvir  (also  in a single  formulation  with  sofosbuvir,  Harvoni®) and  daclatasvir;  the  protease  inhibitor
simeprevir,  and  the  Viekirax® +  ExvieraTM regimen  based  on  the  ritonavir  boosted  protease  inhibitor
paritaprevir;  the  NS5A  inhibitor  ombitasvir,  and  the  non-nucleoside  inhibitor  dasabuvir.  Owing  to  the
budget-breaking  price  of  the newer  oral  medicines,  the  Italian  National  Health  System  elected  to restrict
reimbursement  of  oral  anti-hepatitis  C therapy  to patients  with  advanced  liver  disease  or  transplanted
organs,  and  those  who  are  interferon  unable,  only.  While  this  therapeutic  strategy  harmonizes  with
principles  of  distributive  justice,  at the  same  time  it fuelled  the  argument  of  its  doubtful  cost-effectiveness,
owing  to the  National  Health  System’s  reimbursement  of  the  sole  sofosbuvir  + ribavirin  regimen,  which
has  suboptimal  efﬁcacy  against  the  prevalent  hepatitis  C  virus  genotype  1b.  As a  consequence,  we  are
left  with  a number  of  uncertainties  regarding  the  optimal  treatment  modality  for  certain  subgroups  of
hepatitis  C  patients,  and  the clinical  beneﬁts  provided  by hepatitis  C virus  clearance  in  patients  with
advanced  liver  disease.
©  2015  Editrice  Gastroenterologica  Italiana  S.r.l.  Published  by Elsevier  Ltd.  All  rights  reserved.. Introduction
Owing to the regulatory approval of ﬁrst and second wave of
irectly acting antiviral agents (DAAs) against hepatitis C, the most
waited golden era of interferon-free therapy for chronic hepati-
is C has ofﬁcially begun [1–8]. With all the caveats imposed by
oney constraints, in a few years’ time we expect such a therapeu-
ic breakthrough to translate into substantial clinical beneﬁts for
he many patients who are chronically infected with the hepatitis
 virus (HCV). Recently, a questionnaire based survey conducted
n 63 Hepatology centres scattered throughout Italy and, in par-
llel, a review of the National Health System registries led to the
dentiﬁcation of more than 350,000 such patients, mostly attend-
ng hospital-based Hepatology centres [9]. Included in this cohort
re also 30,000 patients co-infected with the human immune deﬁ-
iency virus (HIV) who are receiving care in specialized Infectious
isease centres, as well as at least 25,000 inmates and 70,000
∗ Correspondence to: Division of Gastroenterology and Hepatology, Fondazione
RCCS Ca’ Granda Ospedale Maggiore Policlinico, University of Milan, Via F. Sforza
5,  20122 Milan, Italy. Tel.: +39 0255035432; fax: +39 0250320410.
E-mail address: massimo.colombo@unimi.it
ttp://dx.doi.org/10.1016/j.dld.2015.04.003
590-8658/© 2015 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. Allindividuals, including legal migrants, who are under the care of
general practitioners and are not referred to tertiary care centres.
These worrisome ﬁgures of HCV epidemiology notwithstanding,
known hepatitis C carriers likely underrepresent the real burden of
HCV disease in Italy, where at least one million chronically infected
individuals are estimated to cluster in the aged strata of the gen-
eral population [10]. Following the marketing of highly effective
and safe, yet budget-breaking, oral regimens to treat HCV infec-
tion, questions have been raised on whether the currently endorsed
lifesaving strategy of treating patients most in need of care will
indeed succeed in reducing hepatitis C-related mortality in our pop-
ulation, and therefore be considered cost-effective. No question,
in fact, that a more cost-effective strategy would be treatment all
infected subjects with the aim of eradicating HCV in the community
and preventing the accumulation of patients with advanced liver
disease; yet this approach cannot be pursued due to money con-
strains [11]. Not surprisingly, therefore, along with other European
countries, the National Health System (NHS) in Italy had to tone
down its ambitious aims ultimately endorsing a lifesaving strategy
of restricting anti-HCV treatment to groups of patients with more
advanced liver disease and those who  are interferon unable [12].
We all acknowledge, however, that such a pragmatic approach was
biased by the suboptimal efﬁcacy of the available sofosbuvir (SOF)
 rights reserved.
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lus ribavirin (RBV) regimen, which even combined with pegylated
nterferon (Peg IFN) or extended for 24 weeks as an all-oral regimen,
id not reach a 90% success rate in all patient groups – now consid-
red a “must have” of HCV care. While awaiting the clinical outcome
f second-wave all-oral combinations, very recently approved for
eimbursement, the following issues on several unresolved “hur-
les” in anti-HCV therapy have arisen: how to optimize treatment
f special groups? What clinical beneﬁts can HCV clearance provide
atients with advanced liver disease? How will patients with renal
mpairment comply with the nucleotide inhibitor SOF, given the
enal excretion of its toxic 007 metabolite? How should surveil-
ance be standardized in patients achieving a sustained virological
esponse (SVR)? Finally, how could patient access to all-oral antivi-
al therapy be improved in the near future?
. The upcoming scenario of hepatitis C therapy with
econd-wave DAAs in Italy
Currently, in Italy reimbursement by NHS has been established
or SOF and for the second wave protease inhibitor simepre-
ir (SMV). In a few months, the NS5A inhibitors daclatasvir
DCV) and ledipasvir (LDV) co-formulated with SOF (Harvoni®),
nd the non-nucleotide inhibitor based regimen 3D from Abb-
ie (Viekirax® + ExvieraTM), will be reimbursed by the NHS, as
ell (Table 1). Currently, subgroups of hepatitis C patients who
re eligible to receive NHS-funded all-oral therapy include Child
ugh A and B cirrhotics and patients with a hepatocellular car-
inoma (HCC) not fulﬁlling the criteria for being listed to liver
ransplantation (LT), who have completely responded to limited
epatic resection or local tumour ablation. Likewise, treatment is
eimbursed for the following groups: patients with post-LT recur-
ent hepatitis C and advanced graft ﬁbrosis (Metavir ≥ F3 or with
brosing cholestatic hepatitis); patients with chronic hepatitis and
ryoglobulinemic syndrome or non-Hodgkin lymphoma; patients
ith chronic hepatitis C and advanced ﬁbrosis (Metavir ≥ F3);
atients with decompensated cirrhosis listed for LT with MELD < 25
r with HCC within Milan criteria and an expected time on the list
f at least 2 months; and ﬁnally patients with any (non-liver) organ
ransplantation and chronic hepatitis C, with Metavir ≥ 2.
able 1
ll oral hepatitis C regimens reimbursed by the Italian National Health System.
Regimen Regimen
Genotype 1 SOF + RBV Genotype 3 SOF + RBV
SOF + LDVa SOF + LDV + RBV
SOF + DCV SOF + DCV + RBV
SOF + DCV ± RBV
SOF + SMV  ± RBV
Viekirax® + ExvieraTM b
Genotype 2 SOF + RBV Genotype 4 SOF + RBV
SOF + RBV
SOF + LDVa
SOF + DCV ± RBV
SOF + SMV  ± RBV
Viekirax® + ExvieraTM b
OF, Sofosbuvir; SMV, Simeprevir; RBV, Ribavirin; DCV, Daclatasvir; LDV, Ledipasvir.
a SOF + LDV: 8 weeks treatment in naïve non-cirrhotic patients; 12 weeks treat-
ent in naive patients with cirrhosis and in treatment experienced patients without
irrhosis; 24 weeks treatment in experienced patients with cirrhosis; 12 weeks
reatment in experienced patients with decompensated cirrhosis with addition of
scending doses of RBV.
b Viekirax® + ExvieraTM: 12 weeks treatment in genotype 1b without cirrhosis; 12
eeks treatment in genotype 1a without cirrhosis and genotype 1b patients with
irrhosis, with addition of RBV; 24 weeks treatment in genotype 1a with cirrhosis,
ith addition of RBV; In genotype 4, 12 weeks + RBV in patients without cirrhosis
nd 24 weeks + RBV in cirrhotics.Disease 47 (2015) 727–733
3. Improving treatment of subgroups of patients with
genotype 1, 3 and 4
It is widely acknowledged that the SOF + RBV combination has
suboptimal therapeutic efﬁcacy in subgroups of patients with hep-
atitis C genotype 1 and 3, particularly those with advanced ﬁbrosis
and those with a previous failure to interferon-based therapy
[1,2,12]. In these populations, the SVR rates are substantially higher
following treatment with a combination of SOF with other DAAs,
as recently validated in ﬁeld practice reports from the US, Canada
and Germany (HCV Target), the US (TRIO) and France (Temporary
Authorization of Use, ATU). In the HCV Target consortium, encom-
passing 38 academic and 15 community medical centres, SOF was
given in association with RBV in less than 10% of the genotype
1 population on the assumption of unsatisfactory SVR rates and
incremental cost of extended treatment to 24 weeks; the associ-
ation of SOF + SMV  was  given for 12 or 24 weeks without RBV in
90% of patients, representing 2/3 of the overall cohort and result-
ing in satisfactory success rates. The SVR rates in fact were 85% in
non-cirrhotics vs 79% in cirrhotics, and 92% in HCV-1b vs 84% in
HCV-1a with a slight reduction of SVR rates (81%) in patients with
a previous protease inhibitors failure [13]. By logistic regression
analysis, low serum levels of albumin, HCV genotype 1a, previous
clinical decompensation and failure to respond to triple therapy
were associated with an increased risk of treatment failure. In the
TRIO network of 31 academic and 119 community sites, treatment
of genotype 1 patients with SOF + SMV  was as successful as in the
HCV Target, resulting in 10% higher rates of response compared to
the association of SOF with Peg IFN + RBV [14]. Overall, the studies
highlighted the remarkable rates of safety and effectiveness of the
combination SOF + SMV  where the need for RBV could be limited
to patients infected by HCV genotype 1a and those with a previous
failure to triple therapy. Surprisingly enough, the French study ATU
reported unprecedented rates of therapeutic success for SOF + RBV
combination therapy (87%) in a cohort enriched with cirrhotics and
previous failures to triple therapy, largely exceeding the outcome of
registration trials (Table 2a). Overall, while ﬁeld practice studies in
the US validated the investigator-driven, proof-of-concept Cosmos
study on SOF + SMV, the ATU study in France conﬁrmed the safety
and efﬁcacy of the SOF + DCV combination in genotype 1 patients
with advanced liver disease, which had been originally tested in a
small proof-of-concept study of patients with less severe hepatitis
C [15]. Further proof of the safety of all combo regimens were the
negligible rates of discontinuation (approximately 6%) that were
attributable to suboptimal adherence rather than to the few, mild
to moderate adverse events recorded in patients with advanced
liver disease. It should be noted, however, that outcomes of real-
life practice with SOF combo regimens have been numerically
overshadowed by the rates of therapeutic success in registration
trials with SOF + LDV and Viekirax® + ExvieraTM, which combines a
ritonavir-boosted protease inhibitor, a NS5A inhibitor and a non-
nucleotide analogue polymerase inhibitor with and without RBV.
The success rates of the latter regimen were particularly impressive
in patients with compensated cirrhosis and severely impaired liver
function, as well as with SOF + LDV in cirrhotics with decompen-
sated liver disease and those who failed previous treatment with
triple therapy with ﬁrst generation DAAs [16]. Of note, in patients
with decompensated liver disease and in treatment-experienced
cirrhotics, a SOF + LDV regimen performed best in association with
RBV (or without RBV if extended to 24 weeks); this was  also the case
for the Viekirax® + ExvieraTM regimen in genotype 1a cirrhotics and
in those with a previous treatment failure. In the Italian scenario,
where the combination of PegIFN + SOF + RBV has long been the
strongest, yet suboptimal, option available to treat HCV genotype
1 with Metavir 3 and 4 ﬁbrosis, a majority of these patients has
been warehoused until the availability of more potent all-oral SOF
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Table  2a
Field practice studies in the treatment of hepatitis C virus genotype 1 patients.
Regimens Weeks Population Number SVR Study
SOF + SMV  (±RBV) 12/24 Metavir F0/3 All 784 85% HCV Target USA
Metavir F4 79%
HCV1b 92%
HCV1a 84%
PI  failures 54 81%
SOF  + RBV 24 Metavir F3/4 136 87% ATU Francea
SOF + DCV 12 Metavir F3/4 104 92%
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lOF, Sofosbuvir; SMV, Simeprevir; RBV, Ribavirin; DCV, Daclatasvir; ATU, Temporary
SV,  Asunaprevir; BCV, Beclabuvir; SMV, Simeprevir.
a Previous failures to protease inhibitors (PI).
ombo regimens with DCV, SMV  or LDV, or Viekirax® + ExvieraTM.
n our country, treatment of genotype 1 patients with decompen-
ated cirrhosis remains a therapeutic hurdle, owing to the delayed
pproval of reimbursement of newer DAAs to combine with SOF,
hereas SMV  is the only available DAA in association with SOF,
et of uncertain safety in patients with advanced liver dysfunction.
hile in decompensated patients HCV suppression is lifesaving
nd stands as a prerequisite for improving the outcome of LT, the
urrently available standard of care SOF + RBV is poorly tolerated
nd offers limited chances of SVR even if extended to 48 weeks.
his was clearly demonstrated in the US registration trial where
4 weeks of SOF + RBV led to HCV suppression in 93% of decom-
ensated patients with reversal of ascites and encephalopathy in
ost, however without signiﬁcant rates of HCV eradication [17].
CV eradication was instead achieved in 90% of genotype 1 decom-
ensated patients who received 12 weeks LDV + SOF + RBV, which
esulted in an improvement of Child Pugh score in most patients
18], an outcome conducive of improved prognosis also for those
atients who are not listed for LT. While waiting for SOF combo
herapy with LDV or DCV to become reimbursable, most centres
n Italy have had no better option than prescribing 24 weeks of
OF + RBV as a standard of care for decompensated patients.
Another difﬁcult to treat population are cirrhotics infected with
enotype 3 and a previous failure to Peg IFN + RBV. While approxi-
ately 90% of treatment-naive genotype 3 patients with any degree
f disease severity obtained SVR following 24 weeks of SOF + RBV,
his same regimen provided suboptimal rates of SVR (62%) in
reatment-experienced patients with cirrhosis [19]. While the rea-
ons for treatment refractoriness of the latter group remain elusive,
he rates of cure with SOF can only marginally be improved by com-
ination with DCV + RBV (69%) or LDV + RBV (73%) [14]. A higher
VR rate was reported in 12 treatment-experienced cirrhotics
eceiving 12 weeks of SOF + PegIFN + RBV (83%), yet one must con-
ider in this study the under representation of HCV genotype 1b (the
ost common in Italy) and the recruitment of patients ﬁt to receive
nterferon, only. While waiting for availability of a 12-week com-
ination of SOF plus the 2nd generation NS5A inhibitor GS-5816,
hich in combination with RBV led to the highest response rates
n genotype 3 patients (96%) [20], a widespread policy in Italy is
o warehouse genotype 3 patients with minimal ﬁbrosis and treat
xperienced cirrhotics, since 24 weeks of SOF is reimbursed at a
ost similar to the 12-week course of triple therapy.
More reassuring is the therapeutic outlook of genotype 4-
nfected patients, where, however, an issue is the lack of robust
ata to demonstrate the superiority of newer combo regimens
ver the standard of care SOF + RBV, particularly in Egyptian
ncestry populations. Indeed, the standard of care of 24 weeks
ith SOF + RBV provided 100% rates of SVR in a small group ofreatment-naïve patients of Egyptian ancestry, a success rate that
as slightly attenuated (87%) in treatment-experienced patients of
he same descent. Noteworthy, 2nd generation 12-week regimens
ike LDV + SOF and the BMS  TRIO (asunaprevivir + becabluvir + DCV)orization for Use; TN, treatment naïve; TE, treatment experienced; LDV, Ledipasvir;
are of comparably high efﬁcacy in naive patients and predictably
of lower cost than SOF and RBV, particularly in treatment experi-
enced patients [21–23, Marcellin P, personal communication]. In
the ATU study of SOF, a small group of genotype 4 treatment-
experienced patients with advanced ﬁbrosis of mixed geographical
origin (France, Egypt and Middle East) treated with either the
standard of care (SOF + RBV) or a combo of SOF  plus either SMV
or DCV, achieved SVR rates >82% (Table 2b). While this data needs
to be validated in larger studies, there is also a need to explore
the effectiveness of these regimens in genotype 4-infected patients
with non-d subtypes.
4. Improving treatment of patients listed for LT and with
HCC
The efﬁcacy of all-oral regimens to revert clinical decom-
pensation in interferon-unable hepatitis C patients listed for LT
represents a real breakthrough in transplant medicine. In a study
of 25 cirrhotic patients with portal hypertension randomized to
SOF + RBV for 48 weeks, a majority of patients achieved virological
clearance on-therapy (100% in Child Pugh A and 65% in Child Pugh
B) with a signiﬁcant reduction in the rates of clinical events like
ascites and encephalopathy, ultimately resulting in an increased
chance of delisting [17]. While it is still unknown whether SVR
is also associated with a reduction in liver-related mortality in
patients who are delisted, in listed patients the prevention of HCV
recurrence stands as the real end-point to improve LT outcome,
a goal that can be achieved by either pre-LT or post-LT antiviral
therapy. Indeed, recurrent hepatitis C is known to have an accel-
erated course, which may  lead to graft or patient death in more
than 30% of the cases in the ﬁrst 5 years post-LT. In a phase 2 study
of 61 genotype 1/4 patients awaiting LT who received SOF  + RBV
until transplant or up to 48 weeks, 92% of patients tested HCV RNA
<25 IU/mL at time of transplantation and 29/46 achieved SVR12
(69%). Given that the number of consecutive days with undetectable
HCV RNA prior to LT was  the strongest predictor of post-transplant
cure, the current strategy to prevent post-LT HCV recurrence is
to treat the patient as long as needed to achieve 30 days of HCV
RNA undetectability pre-LT [24]. Another approach to prevent the
life-threatening complications of recurrent HCV is to start antivi-
ral therapy after LT, before graft cirrhosis ensues. A pilot, single
arm study assessed the safety and efﬁcacy of SOF and a dose-
escalating regimen with RBV for 20 weeks in 40 patients with
hepatitis C recurrence, including only 12 patients with compen-
sated cirrhosis. SVR12 was  achieved in 70% of patients without any
signiﬁcant adverse events or episode of rejection [25]. This was
also the outcome of antiviral treatment of severe recurrent HCV
within the compassionate use programme with SOF in 104 liver
recipients with ﬁbrosing cholestatic hepatitis or decompensated
cirrhosis who received therapy up to 48 weeks post-LT. The rates
of SVR were 70% in patients with ﬁbrosing cholestatic hepatitis,
which is a severe early graft dysfunction due to a direct cytopatic
730 M. Colombo / Digestive and Liver Disease 47 (2015) 727–733
Table 2b
All oral treatments evaluated in hepatitis C virus genotype 4 patients.
Regimens Weeks Study No. SVR
SOF + RBV 24 Egyptian Ancestry TN 14 100%
Egyptian Ancestry TE 15 87%
LDV/SOF 12 SYNERGY TN/TE 20 95%
ASV  + BCV + DCV 12 Exploratory Study TN 21 100%
SOF  + RBV 24 ATU, France 20 82%
SOF  + SMV 12 11 82%
SOF  + DCV 12 11 87%
S  Authorization for Use; TN, treatment naïve; TE, treatment experienced; LDV, Ledipasvir;
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Fig. 1. A meta-analysis of 129 studies evaluating the effects of sustained virologicalOF, Sofosbuvir; SMV, Simeprevir; RBV, Ribavirin; DCV, Daclatasvir; ATU, Temporary
SV,  Asunaprevir; BCV, Beclabuvir; SMV, Simeprevir.
ffect of HCV, whereas it was lower (48%) in those with estab-
ished end-stage cirrhosis. The disadvantage of delayed treatment
f recurrent hepatitis C was highlighted by a small compassionate
se programme with SOF + DCV in genotype 1 and 4 recipients with
evere recurrent hepatitis C who were not eligible to interferon-
ased therapies [26] and by the registration trial of 12 weeks of
OF + LDV + RBV [27]. In the latter study, the SVR rates were 100%
n patients with Metavir F0-4, in 85% of Child Pugh B and 60% of
hild Pugh C patients post LT, only. While these data clearly favour
reatment of hepatitis C pre-LT to prevent severe complications
f recurrent hepatitis C, one obvious question is how to optimize
reatment of patients with decompensated liver disease and those
ho undergo LT earlier than anticipated. In our centre, an option is
 bridging SOF + RBV regimen from the pre-LT to the post-LT phase,
esulting in a shortened duration of post-LT treatment needed to
ermanently eradicate the infection [28].
Another reason of concern in the treatment of patients with
dvanced liver disease is the risk of HCC development, which is
ot removed in all patients obtaining SVR [29]. In viremic patients
ith HCC, anti-tumour treatment is often hampered by portal
ypertension, which increases the risk of clinical decompensation
ollowing hepatic resection or chemoembolization in fragile cir-
hotic patients [30]. Reversal or prevention of decompensation and,
n general, improvement of Child–Pugh status is a demonstrated
eneﬁt of all-oral anti-HCV therapy, and is expected to increase
atient access to effective anti-HCC therapy. The beneﬁt of HCV
learance in patients with advanced disease could be even greater
n patients with multiple tumour nodules in which local ablation
herapy is contraindicated due to the risk of treatment-related clin-
cal decompensation. In the transplantation ﬁeld, an additional
eneﬁt of all-oral therapy is delisting of SVR patients who  may
eceive curative local ablative therapies or hepatic resection, clearly
n the assumption that HCV clearance ampliﬁes the applicability of
nti-HCC invasive procedures while reducing the risk of liver failure
nd subsequent primary tumours. Similarly, indication to LT might
e expanded in selected SVR patients exceeding Milan criteria, as
he increase in the risk of tumour recurrence post-LT may  be offset
y the prevention of hepatitis C recurrence.
. Does SVR improve the outcome of advanced hepatitis C?
Retrospective studies in patients with chronic hepatitis C have
ndependently highlighted a number of clinical beneﬁts of SVR to
nterferon-based regimens, the most important being a decline in
iver-related and all-cause mortality [31–33]. This was  also the
onclusion of a recent meta-analysis of 129 studies encompassing
3,309 patients, which, on the other hand, stressed the persistence
f the risk of liver transplantation, HCC and death from any cause in
everal patients achieving SVR to interferon-based regimens (Fig. 1)
34]. While the reasons for the residual risk of end-stage liver com-
lications in SVR patients are rather elusive, likely culprits are
omorbidities such as diabetes, renal failure and cardiovascular dis-
ase that concur in a signiﬁcant number of HCV-infected patientsresponse on the risk of liver transplant, hepatocellular carcinoma, death and re-
infection in hepatitis C populations. SVR, sustained virological response; AVG FU,
average follow-up; HIV, human immunodeﬁciency virus; HCV, hepatitis C virus.
with HCC and cannot be cured by interferon [33,35,36]. One argu-
ment against our strategy of restricting all-oral therapy to patients
with severe hepatitis only is data correlating the post-SVR risk of
HCC with the severity of pre-existing liver disease [29] and, in geno-
type 1, with the prevalence of genetic mutations in the amino acid
70 and/or 91 of the HCV core region [37]. While the ﬁrst inter-
pretation favours treatment of patients with early infection rather
than those with advanced liver disease, these observations alto-
gether question the cost-beneﬁt of the current life-saving strategies
dictated by money constraints, which justify treatment prioriti-
zation of patients with more advanced disease. This is also the
message of a preliminary report of 120 patients with advanced
cirrhosis who  were successfully treated with a combination of
SOF + SMV  for 12 weeks; HCC risk persisted in patients with mod-
erate hepatic dysfunction whereas patients with MELD > 12 did
not appear to improve clinically while remaining in need of LT
even after achieving SVR (Shiffman et al., personal communication).
Overall, previous studies with interferon and preliminary reports of
ﬁeld practice with all-oral DAAs highlight a failure of SVR to provide
a universal cure of patients with advanced HCV cirrhosis, whereas
they argue against cost-effectiveness of prioritizing patients with
advanced ﬁbrosis to DAA therapy.
6. Renal disease remains a major subgroup needing study
In the interferon era, early treatment of HCV in patients with
diabetes was associated with a decline in the rates of end-stage
renal disease, myocardial infarction and stroke whereas satisfac-
tory rates of HCV cure were achieved in a subset of patients
on chronic haemodialysis [38,39]. SOF-based regimens are con-
traindicated in patients with creatinine clearance <30 ml/min
owing to the potential toxicity caused by the accumulation of
its 007 metabolite cleared by kidney. Currently, in patients with
chronic kidney disease the efﬁcacy and safety of such regimens
as Viekirax® + ExvieraTM and grazoprevir + elbasvir for genotype 1,
SOF + RBV for genotypes 1 and 3 and SMV  + DCV for genotypes 1b
M. Colombo / Digestive and Liver Disease 47 (2015) 727–733 731
Table  3
Ongoing registration trials in chronic kidney disease patients with hepatitis C.
Regimen Phase Genotype Status ClinTrials.gov Id.
Chronic kidney disease
AbbVie 3D 3 1 Recruiting NCT02207088
Grazoprevir + Elbasvir 2,3 1 Ongoing NCT02092350
SOF  + RBV 2 1,3 Recruiting NCT01958281
SMV  + DCV 2 1b,4 Recruiting (TMC435HPC2018)
Kidney transplant
LDV + SOF 2 1,4 Recruiting NCT02251717
SOF, Sofosbuvir; RBV, Ribavirin; SMV, Simeprevir; DCV, Daclatasvir; LDV, Ledipasvir.
Table 4
Proof of concept studies of short duration all oral therapy for hepatitis C.
Regimen Genotype N. patients Weeks SVR Study
Harvoni® + GS-9669 (TN) 1,4 10 4 90% Kohli (2013)
Harvoni® + GS-9451 (TN,TE) 1,4 20 6 100% Kohli (2013)
Grazoprevir + Elbasvir + SOF 1a,1b 30 6 87% Lawitz (2014)
Harvoni® + RBV 1a,1b 216 8 93% Kowdley (2014)
ACH-3102 + SOF 1a,1b 30 8 100% Gane (2014)
8 >88% Gane (2014)
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Fig. 2. The real issue of the life-saving strategy of treating patients with advanced
hepatitis C only: high risk of hepatocellular carcinoma in aged patients with cir-
rhosis following a sustained virological response. Patients were stratiﬁed in 3 riskSOF  + GS-5816 3 104 
N, treatment naïve; TE, treatment experienced; SOF, sofosbuvir; RBV, Ribavirin.
nd 4, are being tested in phase 2 and 3 trials. Less explored is the
ntiviral treatment of patients with a kidney graft, where patients
ith HCV genotypes 1 and 4 are being recruited in a phase 2 study
ith LDV + SOF, only (Table 3). One major point of interest of stud-
es in renal disease patients is whether successful anti-HCV therapy
ill favourably impact kidney function, since in some patients renal
ailure may  be accelerated by HCV-related glomerulonephritis.
. Surveillance strategies in SVR patients
The reports of a residual risk of HCC in hepatitis C patients
btaining SVR to interferon-based regimens has set the stage for
ecommending liver cancer surveillance in patients who clear
CV, particularly in those with pre-treatment severe liver disease
30]. This recommendation was clearly validated by a retrospec-
ive study in Taiwan of 871 patients with SVR to PegIFN + RBV
herapy, where 50 patients developed HCC during a follow-up of
.5–114 months and an association between risk of developing
ancer, patient age and disease severity was reported [29]. The
nding that the annual HCC risk was 5% in patients with advanced
brosis aged >60 years and between 1.8 and 0.3% in those aged
60 years with less severe hepatitis (Fig. 2) provided insights for
ptimizing ultrasound-based surveillance of SVR patients. Further-
ore, this heightens the issues related to cost-beneﬁt of the current
herapeutic strategies based on prioritization of DAA therapy in
atients with advanced liver ﬁbrosis. Given the rates of all-cause
ortality in patients with HCV-related cirrhosis who  achieved
n SVR, surveillance should also include careful monitoring of
xtra-hepatic complications. A study in Denmark clearly demon-
trated that 24% of HCV patients with cirrhosis had one or more
omorbidities related to cardiovascular, neurological, pulmonary
r neoplastic disease, accounting for a substantial increase in the
ortality compared to cirrhosis patients without comorbidities
35]. In the US, surveillance of SVR patients is strongly recom-
ended in cirrhotics and hepatitis C patients with comorbidities
uch as overweight, diabetes and chronic alcohol abuse.
. The future: how to improve patient access to therapy
nd prevent reinfection
The skyrocketing, budget-breaking prices of the newer anti-
CV medicines are a real hurdle, which limits patient access tolevel  classes based on age (≥60 years), platelet count (≤150,000 × 109/L), alpha-
fetoprotein ≥20 mg/ml and liver ﬁbrosis Metavir F3 vs F4. HCC, hepatocellular
carcinoma.
HCV therapy even in resource-rich countries. Due to the strict
correlation that exists between pricing of a new drug and the vol-
ume  of treatments negotiated, a single body negotiation for all
European countries might help downsize the cost of newer anti
HCV molecules; in the meantime we wait for market competition
between companies manufacturing all-oral anti HCV regimens to
bring the price of these medicines down to more reasonable lev-
els. The development of even shorter duration regimens (6 weeks)
would also enable cost savings, and this can be achieved through a
combination of different classes of second generation DAAs. While
this strategy stands as a pragmatic approach to deliver less expen-
sive anti-HCV therapy which couples convenience and patient
compliance, it also needs to be predictable for different patient
populations and must have a real clinical rationale. Preliminary
studies indicate that 4- to 8-week regimens can provide optimal
rates of SVR, however with the caveat that only non-cirrhotic popu-
lations have been tested so far (Table 4) [40–44]. Along the same
line is development of a pangenotypic regimen with all-oral DAAs,
with the ultimate goal of removing the barriers represented by the
need of sophisticated virological testing. Currently, point of care
tests like an oral HCV assay and non-invasive tools to stage liver
disease severity, i.e., Fibrotest and Fibroscan, are widely adopted.
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inally, the fact that all currently available therapies failed to induce
rotective immunity following HCV clearance poses a threat to
uccessful eradication campaigns in geographical areas or com-
unities with high HCV endemicity. Existing data pinpoints the
mportance of host immunity in association with second wave
AAs in the clearance of HCV. In geographical areas like Japan,
orea and the Far East where the favourable IFN lambda 4 geno-
ype CC predominates among the general population, the SVR rates
o SOF and LDV were 100%, whereas in both registration and ﬁeld
ractice studies, all HCV1b patients who relapsed to SOF based ther-
py were non-CC genotype. Notably, the interim report of the C
WIFT trial shows that patients with residual viraemia at the end
f a 4-week therapy course become transiently HCV RNA negative
t week 2 of post-treatment follow-up without receiving any fur-
her antiviral treatment [43]. The clear message of the study that
nnate immunity matters in achieving HCV eradication in patients
xposed to all-oral therapy, matches the need to protect high-risk
atients from reinfection with HCV. In fact, therapeutic vaccines
ased on epitopes of the HCV envelope proteins that are involved
n virus neutralization are being investigated in patients who suc-
essfully responded to DAAs, for their ability to boost virus-speciﬁc
mmunity.
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